Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 6, 2009 - Issue 8
Submit an article Journal homepage
226
Views
76
CrossRef citations to date
0
Altmetric
Reviews

Targeting anti-HIV drugs to the CNS

Kavitha S Rao Graduate student, Lerner Research Institute, Cleveland Clinic, Department of Biomedical Engineering, Cleveland, OH 44195, USA
, PhD,
Anuja Ghorpade Professor and Vice Chair, University of North Texas, Department of Cell Biology and Genetics, Fort Worth, TX 76107, USA
, PhD &
Vinod Labhasetwar Graduate student, Lerner Research Institute, Cleveland Clinic, Department of Biomedical Engineering, Cleveland, OH 44195, USA; Professor and Staff, Cleveland Clinic, Department of Biomedical Engineering/ND-20, 9500 Euclid Avenue, Cleveland, OH 44195, USA +1 216 445 9364; +1 216 444 9198; [email protected]
, PhD
Pages 771-784 | Published online: 30 Jun 2009

Bibliography

  • HIV/AIDS Statistics and Surveillance. CDC, 2006. Available from: http://www.cdc.gov/hiv/topics/surveillance/ basic.htm#ddaids
  • AIDS Epidemic Update. UNAIDS, 2007. Available from: http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf
  • Lange CG, Lederman MM, Medvik K, et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003;17:2015-23
  • Fleury S, de Boer RJ, Rizzardi GP, et al. Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Nat Med 1998;4:794-801
  • Sachsenberg N, Perelson AS, Yerly S, et al. Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med 1998;187:1295-303
  • Paparizos VA, Kyriakis KP, Kourkounti S, et al. The Influence of a HAART regimen on the expression of HIV-associated Kaposi sarcoma. J Acquir Immune Defic Syndr 2008;49:111 Letter United States
  • Kaul M. HIV's double strike at the brain: neuronal toxicity and compromised neurogenesis. Front Biosci 2008;13:2484-94
  • Folks T, Kelly J, Benn S, et al. Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol 1986;136:4049-53
  • Nottet HS, Persidsky Y, Sasseville VG, et al. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunol 1996;156:1284-95
  • An SF, Groves M, Giometto B, et al. Detection and localisation of HIV-1 DNA and RNA in fixed adult AIDS brain by polymerase chain reaction/in situ hybridisation technique. Acta Neuropathol 1999;98:481-7
  • Bagasra O, Lavi E, Bobroski L, et al. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. Aids 1996;10:573-85
  • Wiley CA, Achim CL, Christopherson C, et al. HIV mediates a productive infection of the brain. Aids 1999;13:2055-9
  • Canto-Nogues C, Sanchez-Ramon S, Alvarez S, et al. HIV-1 infection of neurons might account for progressive HIV-1-associated encephalopathy in children. J Mol Neurosci 2005;27:79-89
  • Gorry PR, Ong C, Thorpe J, et al. Astrocyte infection by HIV-1: mechanisms of restricted virus replication, and role in the pathogenesis of HIV-1-associated dementia. Curr HIV Res 2003;1:463-73
  • Brack-Werner R. Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis. Aids 1999;13:1-22
  • Wiley CA, Schrier RD, Nelson JA, et al. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA 1986;83:7089-93
  • Grant I. Neurocognitive disturbances in HIV. Int Rev Psychiatry 2008;20:33-47
  • Letendre S, McCutchan JA, Ellis RJ. Neurologic complications of HIV disease and their treatment. Top HIV Med 2008;16:15-22
  • Ances BM, Ellis RJ. Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 2007;27:86-92
  • Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69:1789-99
  • Hinkin CH, Castellon SA, Atkinson JH, et al. Neuropsychiatric aspects of HIV infection among older adults. J Clin Epidemiol 2001;54(Suppl 1):S44-52
  • Wiseman MB, Sanchez JA, Buechel C, et al. Patterns of relative cerebral blood flow in minor cognitive motor disorder in human immunodeficiency virus infection. J Neuropsychiatry Clin Neurosci 1999;11:222-33
  • Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004;63:2084-90
  • Maschke M, Kastrup O, Esser S, et al. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry 2000;69:376-80
  • Nath A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis 2002;186(Suppl 2):S193-8
  • Rao KS, Reddy MK, Horning JL, et al. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 2008;29:4429-38
  • Stewart SA, Poon B, Song JY, et al. Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J Virol 2000;74:3105-11
  • Corasaniti MT, Strongoli MC, Piccirilli S, et al. Apoptosis induced by gp120 in the neocortex of rat involves enhanced expression of cyclooxygenase type 2 and is prevented by NMDA receptor antagonists and by the 21-aminosteroid U-74389G. Biochem Biophys Res Commun 2000;274:664-9
  • Alirezaei M, Watry DD, Flynn CF, et al. Human immunodeficiency virus-1/surface glycoprotein 120 induces apoptosis through RNA-activated protein kinase signaling in neurons. J Neurosci 2007;27:11047-55
  • Ghafouri M, Amini S, Khalili K, et al. HIV-1 associated dementia: symptoms and causes. Retrovirology 2006;3:28
  • Cook JE, Dasgupta S, Middaugh LD, et al. Highly active antiretroviral therapy and human immunodeficiency virus encephalitis. Ann Neurol 2005;57:795-803
  • Boisse L, Gill MJ, Power C. HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin 2008;26:799-819
  • Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007;45:174-82
  • Robinson-Papp J, Byrd D, Mindt MR, et al. Motor function and human immunodeficiency virus-associated cognitive impairment in a highly active antiretroviral therapy-era cohort. Arch Neurol 2008;65:1096-101
  • Rumbaugh JA, Nath A. Developments in HIV neuropathogenesis. Curr Pharm Des 2006;12:1023-44
  • Clifford DB. HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med 2008;16:94-8
  • Tan H, Rader AJ. Identification of putative, stable binding regions through flexibility analysis of HIV-1 gp120. Proteins 2008;74:881-94
  • Kwei GY, Novak LB, Hettrick LA, et al. Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dogs. Pharm Res 1995;12:884-8
  • Lin JH, Chen IW, Vastag KJ, et al. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab Dispos 1995;23:730-5
  • Bocedi A, Notaril S, Narciso P, et al. Binding of anti-HIV drugs to human serum albumin. IUBMB Life 2004;56(10):609-14
  • Greene JN, Poblete SJ, Krieff D. New directions in antimicrobial therapy. Chest Surg Clin N Am 1999;9:39-61, vii-viii
  • Markowitz M, Mohri H, Mehandru S, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005;365:1031-8
  • Ho D. Residual pool of HIV after prolonged combination therapy. 5th Conference on Retroviruses and Opportunistic Infections; Chicago, IL; February 3 1998
  • Ho DD. Therapy of HIV infections: problems and prospects. Bull NY Acad Med 1996;73:37-45
  • Crowe SM, McGrath MS, Elbeik T, et al. Comparative assessment of antiretrovirals in human monocyte-macrophages and lymphoid cell lines acutely and chronically infected with the human immunodeficiency virus. J Med Virol 1989;29:176-80
  • Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 1969;40:648-77
  • Rubin LL, Staddon JM. The cell biology of the blood-brain barrier. Annu Rev Neurosci 1999;22:11-28
  • Crone C, Christensen O. Electrical resistance of a capillary endothelium. J Gen Physiol 1981;77:349-71
  • Chaudhuri JD. Blood brain barrier and infection. Med Sci Monit 2000;6:1213-22
  • Takasawa K, Terasaki T, Suzuki H, et al. In vivo evidence for carrier-mediated efflux transport of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. J Pharmacol Exp Ther 1997;281:369-75
  • Wang Y, Sawchuk RJ. Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. J Pharm Sci 1995;84:871-6
  • Tsuji A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2005;2:54-62
  • Schinkel AH. The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers. Adv Exp Med Biol 2001;500:365-72
  • Thiebaut F, Tsuruo T, Hamada H, et al. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989;37:159-64
  • Dwibhashyam VSNM, Nagappa A. Strategies for enhanced drug delivery to the central nervous system. Indian J Pharm Sci 2008;70:145-53
  • Prokai-Tatrai K, Prokai L, Bodor N. Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design. J Med Chem 1996;39:4775-82
  • Ikeda M, Bhattacharjee AK, Kondoh T, et al. Synergistic effect of cold mannitol and Na(+)/Ca(2+) exchange blocker on blood-brain barrier opening. Biochem Biophys Res Commun 2002;291:669-74
  • Neuwelt EA, Hill SA, Frenkel EP. Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening. Neurosurgery 1984;15:362-6
  • Salahuddin TS, Johansson BB, Kalimo H, et al. Structural changes in the rat brain after carotid infusions of hyperosmolar solutions: a light microscopic and immunohistochemical study. Neuropathol Appl Neurobiol 1988;14:467-82
  • Hynynen K. Focused ultrasound for bloodâ “brain disruption and delivery of therapeutic molecules into the brain. Expert Opinion on Drug Deliv 2007;4:27-35
  • Oztas B, Kucuk M. Intracarotid hypothermic saline infusion: a new method for reversible blood-brain barrier disruption in anesthetized rats. Neurosci Lett 1995;190:203-6
  • Spigelman MK, Zappulla RA, Johnson J, et al. Etoposide-induced blood-brain barrier disruption. J Neurosurg 1984;61:674-8
  • Zhang Y, Schlachetzki F, Pardridge WM. Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther 2003;7:11-8
  • Pardridge WM. Brain drug targeting: the future of brain drug development. Cambridge, U.K.: Cambridge University Press, 2003
  • Coloma MJ, Lee HJ, Kurihara A, et al. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res 2000;17:266-74
  • Pardridge WM. Molecular Trojan horses for blood-brain barrier drug delivery. Curr Opin Pharmacol 2006;6:494-500
  • Tiwari SB, Amiji MM. A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 2006;3:219-32
  • Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx 2005;2:99-107
  • Dusserre N, Lessard C, Paquette N, et al. Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics. AIDS 1995;9:833-41
  • Reddy MK, Labhasetwar V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. FASEB J 2009;23:1384-95
  • Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-60
  • Dhanikula RS, Argaw A, Bouchard JF, et al. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol Pharm 2008;5:105-16
  • Huang RQ, Qu YH, Ke WL, et al. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J 2007;21:1117-25
  • Dutta T, Jain NK. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim Biophys Acta 2007;1770:681-6
  • Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev 2008;60:1037-55
  • Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002;54:759-79
  • Spitzenberger TJ, Heilman D, Diekmann C, et al. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J Cereb Blood Flow Metab 2007;27:1033-42
  • Webb K, Caldwell K, Tresco PA. Fibronectin immobilized by a novel surface treatment regulates fibroblast attachment and spreading. Crit Rev Biomed Eng 2000;28:203-8
  • Lockman PR, Mumper RJ, Khan MA, et al. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 2002;28:1-13
  • Ojewole E, Mackraj I, Naidoo P, et al. Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur J Pharm Biopharm 2008;697-710
  • Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47:65-81
  • Alyautdin RN, Tezikov EB, Ramge P, et al. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul 1998;15:67-74
  • Tosi G, Costantino L, Rivasi F, et al. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Release 2007;122:1-9
  • Kaur IP, Bhandari R, Bhandari S, et al. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008;127:97-109
  • Dechy-Cabaret O, Martin-Vaca B, Bourissou D. Controlled ring-opening polymerization of lactide and glycolide. Chem Rev 2004;104:6147-76
  • Yoo JY, Kim JM, Seo KS, et al. Characterization of degradation behavior for PLGA in various pH condition by simple liquid chromatography method. Biomed Mater Eng 2005;15:279-88
  • Zhang Z, Feng SS. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 2006;27:4025-33
  • Hanson LR, Frey WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008;9(Suppl 3):S5
  • Tadayoni BM, Friden PM, Walus LR, et al. Synthesis, in vitro kinetics and in vivo studies on protein conjugates of AZT: evaluation as a transport system to increase brain delivery. Bioconjug Chem 1993;4:139-45
  • Temsamani J, Rousselle C, Rees AR, et al. Vector-mediated drug delivery to the brain. Expert Opin Biol Ther 2001;1:773-82
  • Hermanson GT. Bioconjugate Techniques. London: Academic Press, 1996
  • Lockman PR, Oyewumi MO, Koziara JM, et al. Brain uptake of thiamine-coated nanoparticles. J Control Release 2003;93:271-82
  • Mishra V, Mahor S, Rawat A, et al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target 2006;14:45-53
  • Dou H, Morehead J, Destache CJ, et al. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 2007;358:148-58
  • Dou H, Destache CJ, Morehead JR, et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 2006;108:2827-35
  • Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004;10:310-5
  • Richard JP, Melikov K, Vives E, et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 2003;278:585-90
  • Temsamani J, Vidal P. The use of cell-penetrating peptides for drug delivery. Drug Discov Today 2004;9:1012-9
  • Zheng L, Yang YD, Lu GC, et al. Extracellular HIV Tat and Tat cysteine rich peptide increase CCR5 expression in monocytes. J Zhejiang Univ Sci B 2005;6:668-72
  • Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997;272:16010-7
  • Derossi D, Calvet S, Trembleau A, et al. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 1996;271:18188-93
  • Schwarze SR, Ho A, Vocero-Akbani A, et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999;285:1569-72
  • Peetla C, Rao KS, Labhasetwar V. Relevance of biophysical interactions with model membrane in predicting cellular uptake: study with TAT peptide-conjugated nanoparticles. Mol Pharm 2009 In press
  • Kravcik S, Gallicano K, Roth V, et al. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J Acquir Immune Defic Syndr 1999;21:371-5
  • Sabatier JM, Vives E, Mabrouk K, et al. Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J Virol 1991;65:961-7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.